FDA proposes Schedule I status for potent kratom derivative 7-OH
The Food and Drug Administration proposed temporarily designating high-potency 7-hydroxymitragynine as a Schedule I drug in July 2025.
Regulatory split on kratom products
Experts agree that guardrails are needed for kratom and its derivatives. Clinicians warn that concentrated 7-OH could be more addictive than natural kratom leaf products. The agency has already moved three less common synthetics into Schedule I without a potency threshold.
Proposed temporary designation details
The proposal would apply only to 7-OH above a certain threshold of potency. This move allows milder, natural kratom products to continue selling under current regulatory rules. The law has not yet been finalized by the agency.
Pressure mounts for action
Advocates and clinicians push for regulation after reports of physical dependence risks. Public health threats from substances like tobacco and Oxycontin prompted previous warnings from FDA leadership. Pressure is increasing to regulate all types of kratom following recent incidents.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.